Showing results (1-10 of 23) with videos related to

Sort By:
Pageof 3
Current Opinion in Rheumatology|May 22, 2013
Hip disease in ankylosing spondylitisBert Vander Cruyssen, Nathan Vastesaeger, Eduardo Collantes-Estévez
Rheumatology (Oxford, England)|July 11, 2009
A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritisNathan Vastesaeger, Stephen Xu, Daniel Aletaha, et al.
International Journal of Rheumatic Diseases|April 17, 2019
Treatment with golimumab or infliximab reduces health resource utilization and increases work productivity in patients with ankylosing spondylitis in the QUO-VADIS study, a large, prospective real-life cohortPascal Claudepierre, Filip Van den Bosch, Piercarlo Sarzi-Puttini, et al.
Clinical and Experimental Rheumatology|August 28, 2018
Clinical and quality of life improvements with golimumab or infliximab in a real-life ankylosing spondylitis population: the QUO-VADIS studyFilip Van den Bosch, Rene-Marc Flipo, Jürgen Braun, et al.
Clinical Rheumatology|April 4, 2018
Regional differences in baseline disease activity and remission rates following golimumab treatment for RA: results from the GO-MORE trialPatrick Durez, Karel Pavelka, Maria Alicia Lazaro, et al.
Annals of the Rheumatic Diseases|October 14, 2011
Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND studyAsta Baranauskaite, Helena Raffayová, N V Kungurov, et al.
Case Reports in Rheumatology|December 2, 2014
Effectiveness and safety of infliximab in two cases of severe chondrocalcinosis: nine years of follow-upJácome Bruges-Armas, Bruno F Bettencourt, Ana R Couto, et al.
Clinical Rheumatology|May 13, 2018
Correction to: Regional differences in baseline disease activity and remission rates following golimumab treatment for RA: results from the GO-MORE trialPatrick Durez, Karel Pavelka, Maria Alicia Lazaro, et al.
Clinical and Experimental Rheumatology|February 10, 2015
Factors influencing the patient evaluation of injection experience with the SmartJect autoinjector in rheumatoid arthritisHendrik Schulze-Koops, Roberto Giacomelli, Wlodzimierz Samborski, et al.
Reumatologia Clinica|March 7, 2014
ASDAS high disease activity versus BASDAI elevation in patients with ankylosing spondylitis as selection criterion for anti-TNF therapyNathan Vastesaeger, Bert Vander Cruyssen, Juan Mulero, et al.
Pageof 3